A newer version of OxyContin, created in an
effort to curb the drug’s abuse, is available now. However, skeptics are still
debating as to whether the newer “abuse proof” pills will actually serve in
reducing addiction statistics. Though the FDA has approved this new version, it
requires manufactures to implement testing to help ensure lower abuse
percentages.
The new form of OxyContin makes crushing,
chewing and dissolving the pills more difficult to addicts seeking to achieve the
heroin-esque high it produces.
As opposed to prior OxyContin versions, the new
pills host a durable gelatin capsule, offering users a 24-hour continuous
release when ingested orally. The design also works to prohibit manipulation
that could result in injected or snorted by addicts.
Where’s the Evidence?
Does it work? In a recent statement released
alongside the new drug’s approval, the FDA warns that “there is no evidence
that the reformulation of OxyContin is less subject to misuse, diversion, addiction,
abuse or overdose.”
Unfortunately, there is currently little
scientific evidence to support claims that the new version will serve in
curbing the drug’s addictive tendencies, an ever-growing issue throughout the
U.S.
As such, the FDA has required Purdue Pharma,
the manufacturer of OxyContin, to research the new pills to help determine
whether they actually work to combat abuse, and if so, exactly how.
The above may be partially due to a 2007 case,
in which Purdue Pharma pleaded guilty to misinforming the public regarding
OxyContin’s safety. Purdue Pharma was ordered to pay a fine of $634.5 million –
which to date, is one of the biggest penalties ever evoked by a
drug-company.